Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma

This image opens in the lightbox

News provided by

ALK

01 Dec, 2021, 09:00 GMT

Share this article

Share toX

Share this article

Share toX

- Results from ALK-sponsored REACT (REAl-world effeCTtiveness of allergy immunotherapy) study have been published in The Lancet Regional Health – Europe

- REACT demonstrated the real-world effectiveness of allergy immunotherapy (AIT) – including ALK products – in allergic rhinitis and asthma, including reduced medication use, fewer asthma exacerbations, and improved asthma control

- The study included patients treated with AIT for the three major allergens: house dust mites, grass pollen and tree pollen

- The benefits were sustained for up to nine years and further substantiate existing evidence from randomised, controlled trials (RCTs), while offering new information about the effects of AIT beyond the usual RCT follow-up period

COPENHAGEN, Denmark, Dec. 1, 2021 /PRNewswire/ -- ALK (ALKB: DC) (OMX: ALK B) (OMX: AKABY) (OMX: AKBLF) today announced that results from the REACT study, a large retrospective real-world study comprising more than 92,000 patients with respiratory allergies, have been published in the research journal, The Lancet Regional Health – Europe (https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00261-1/fulltext) – a regionally-focused journal from the publisher of the world's leading medical research journal, The Lancet. The study was authored by leading experts in the field of allergy immunotherapy and real-world evidence.

The study, which is the first of this type and scale within allergy immunotherapy (AIT), was initiated by ALK in 2019 to evaluate the long-term effects of AIT treatment in allergic rhinitis patients with, or without asthma. ALK worked closely with the scientific community to ensure the robustness of the study and the highest possible quality of the data generated, with the aim of informing the right treatment decisions by providing healthcare professionals with best in both clinical and real-world evidence.  

The primary objective of the study was to assess the impact of AIT on the use of symptomatic treatments by people with allergic rhinitis (AR), with or without asthma.

Sustained long-term effect in real world

In the study, 46,024 patients with AR, with or without asthma, and treated with AIT, were compared to an equal number of similar patients with AR not treated with AIT. AIT treatment was associated with long-term sustained reductions in the use of AR and asthma medication for up to nine years after treatment initiation. Patients with pre-existing asthma treated with AIT were more likely to step down their asthma treatment regimens, with a reduced likelihood of stepping up again. Furthermore, AIT was associated with a preventative effect on severe asthma exacerbations and receiving a pneumonia diagnosis over the nine years. In addition, patients treated with AIT had fewer in-patient stays and shorter stays if admitted to hospital. A low frequency of anaphylaxis cases around AIT initiation was recorded.

REACT complements the findings from RCTs

The disease-modifying effects of AIT had previously been confirmed by ALK in a series of RCTs over the past 10 years. Each of these spanned a five-year period comprising three years of treatment with once-daily SQ grass SLIT-tablets, followed by two years of follow-up. In the REACT study, the real-world effectiveness of AIT was confirmed with a trend lasting more than nine years from treatment initiation, extending the evidence from RCTs over a longer period.

To date, two large RCTs with SQ house dust mite SLIT-tablets have confirmed the efficacy of AIT in the treatment of allergic asthma. The REACT study confirms that these benefits of AIT are also seen in the real world, and that the benefits can be sustained for up to nine years.

REACT has also added knowledge to the existing evidence base from RCTs around potential new benefits of AIT treatment, such as a decreased risk of pneumonia and hospitalisation.

Henrik Jacobi, ALK's Executive Vice President of Research and Development, said: "The core value proposition of AIT is its disease-modifying potential and, in particular, its ability to have a long-lasting effect, even after treatment ends. Long-term data as provided by the REACT study are therefore of fundamental importance."

Henrik Jacobi added: "These results build on ALK's long-standing commitment to conduct RCTs for our AIT products, documenting their benefits for both adults and children. The results also illustrate the advantages of monitoring the effectiveness of AIT products over the longer term, so that the full benefits can be documented and clearly demonstrated to prescribers, payers and patients around the world."

Benedikt Fritzsching, lead author of the REACT study said: "While the efficacy and safety of AIT administered – for example as SLIT-tablets – for the most common respiratory allergies have been demonstrated in RCTs, uncertainty around how AIT works in clinical practice has remained. The findings of the REACT study emphasised AIT as an effective and well-tolerated treatment option for patients with respiratory allergies and demonstrated some interesting new benefits. For healthcare practitioners, these findings provide important complementary evidence that will help inform treatment decisions for the benefit of patients with respiratory allergies."

REACT is part of ALK's new REWEAL programme, which has been initiated to supplement the current evidence base for AIT by collating "real-world" patient data on the use of AIT from independent sources in multiple countries. For more information on REWEAL, visit www.reweal.net.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

About The Lancet Regional Health – Europe

The Lancet Regional Health – Europe is an open access journal, part of The Lancet's global initiative to advocate for health-care quality and access in all regions of the world. The journal fosters the advance of clinical practice and health policy in the European region, with the ultimate goal of improving health outcomes. It aspires to increase the quality of regional and national health research.

The journal publishes high-quality original research that advocates change in, or illuminates, clinical practice and health policy in the European region. It also considers relevant reviews, commentaries, and opinion pieces. The journal invites submissions that are pertaining to regional health topics, including but not limited to prevention and management of infections and non-communicable diseases, improvement of healthy ageing, mental health, and reduction of health inequalities.

The journal can be found at www.thelancet.com/journals/lanepe/home.

Logo - https://mma.prnewswire.com/media/1696953/ALK_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.